I lead a multi-disciplinary research group focused on abnormalities affecting haematopoietic (blood cell) development which leads to haematological malignancies (blood cancer). More recently, through the funding of three consecutives Blood Cancer UK Programmes, project grants supported by Charities and RCUK my work has focused on the identification of novel targets, biomarkers and potential drug targets for the treatment of one of these cancers - acute myeloid leukaemia (AML).In particular, I investigate the roles of a number of candidate genes including RUNX1-ETO, metabolic proteins, S100 protiens, Wnt signalling, CD200 and the production of reactive oxygen species (ROS) in leukamogenesis. I am interested in how the process of haematopoietic development in stem and progenitor populations is dysregulated by these genes in AML.